Table 1. CELLULAR PATHWAYS WHOSE ACTIVITY IS AFFECTED BY SOMATIC ALTERATIONS IN LUNG CANCERS *.
| PATHWAY | AC | SQCC | SCLC | |||
|---|---|---|---|---|---|---|
| % | Genes involved | % | Genes involved | % | Genes involved | |
| RTK | 50% | EGFR, ALK, MET, ERBB2, ROS, RET | 27% | EGFR, FGFR1-3, ERBB2, ERBB3, DDR2 | 6% | FGFR1 |
| RAS/RAF | 25% | KRAS, NF1, BRAF, NRAS | 22% | NF1, KRAS, HRAS, NRAS, RASA1, BRAF | ||
| PI3K/AKT | 10-12% | PIK3CA, PTEN, AKT1 | 59% | PIK3CA, PTEN, AKT1, AKT2, AKT3, TSC1-2 | 10% | PTEN |
| LKB1/AMPK | 15-30% | LKB1 | ||||
| TP53 | 50% | P53, MDM2 | 80% | TP53 | 80-90% | TP53 |
| RB1/ CDKNA2 | 15-20 | CDKNA2 | 79% | CDKNA2, RB1 | 100% | RB1, CCNE1 |
| MYC | 30% | MYC | 16-30% | MYC, MYCN, MYCL | ||
| Epigenetic regulation | 22% | SMARCA4, ARID1A, SETD2 | 20% | MLL2 | 19% | EP300, CREBBP, MLL |
| Developmental pathway | 20% | NKX2.1/TTF1 | 44% | SOX2, TP63, NOTCH1, NOTCH2, ASCL4, FOXP1 | 20% | SLIT2, EPHA7 |
| Oxidative stress response | 10% | KEAP1 | 34% | KEAP1, NRF2, CUL3 | ||
*
The genes involved in each type of lung cancer are listed in order of the frequency of alterations found